In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
New evidence indicates that depression can impact cancer outcomes following chemotherapy.
An analysis of data from Danish women with early-stage breast cancer assessed women's risk of receiving nonguideline treatment for their disease if they had a prior diagnosis of depression or prior treatment with antidepressants.
Nearly one in five cancer survivors are taking medication for depression or anxiety years later.
Changes in depression symptoms over time are associated with differences in survival among patients with lung cancer, especially those with early stage disease.
Nearly 25% to 33% of family caregivers of patients with advanced cancers report high levels of anxiety and depression symptoms, as well as significant time providing care.
Treatment with methylphenidate is not effective for depression in SSRI-treated patients with advanced cancer in hospice or receiving palliative care.
Palliative Care-Led Support vs Usual Care: Not Significantly Different for Anxiety and Depression in Cancer Patients' Family MembersJuly 06, 2016
Palliative care-led informational and emotional support meetings do not reduce anxiety or depression symptoms and may increase posttraumatic stress disorder (PTSD) symptoms in family members of patients with chronic critical illness.
A recent study examined depression and anxiety among family caregivers of patients with incurable cancer and sought to identify factors linked to these symptoms.
Socioeconomic status and features of physical health rather than tumor characteristics were associated with symptoms of depression among long-term survivors of colorectal cancer.
Benefits of light therapy include both decreasing depressive symptoms and normalizing circadian rhythms in cancer survivors.
Depressive Symptoms Linked to Worse Survival Following Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive SurgeryFebruary 23, 2016
A study examined the relationship between depression and survival for patients undergoing hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery.
Hematopoietic cell transplantation (HCT)-related concerns at the time of hospital discharge predict increases in depression but not in anxiety.
Researchers observed significant changes in health-related quality of life (HRQoL), depression, and sexual function among patients with breast cancer receiving chemotherapy.
Depression is a significant predictor of 5-year survival and recurrence in patients with head and neck cancer. These findings represent one of the largest studies to report on the impact of depression on cancer survival.
Risk of death from all causes is 45% higher in women with breast cancer and a subsequent diagnosis of depression, according to a recent study. This finding could help identify those women most at risk for depression and in need of support.
Depression and antidepressant use may not be associated with increased risk of breast cancer.
Depression may increase the intensity of postoperative acute pain in women with breast cancer.
The USPSTF urges that primary care physicians regularly screen for depression in all adult patients (B recommendation).
Researchers have found that combined use of antidepressants and NSAID painkillers is associated with an increased risk of bleeding.
Depression in patients with brain cancer is easily overlooked by clinicians.
Women with breast cancer are at an increased long-term risk for developing first depression.
Music therapy improves anxiety, depression, pain, and fatigue in patients with cancer.
Patients diagnosed with breast cancer, head and neck cancer, and malignant melanoma are particularly at risk for disorders such as anxiety or depression.
Men with diagnosed depressive disorders are less likely to pursue definitive treatment options for prostate cancer and more likely to have poorer outcomes.
Two classes of antidepressants improve symptoms of depression in cancer patients, according to a comprehensive review of treatments.
Depressed men with a diagnosis of intermediate- or high-risk prostate cancer have worse overall outcomes.
Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.
Depression and anxiety, not just inflammation, predict pain intensity and interference with daily life among women recovering from gynecologic cancer surgery.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|